Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSM insider Martina Flammer filed a notice to sell 795 shares of common stock through Merrill Lynch on or about 02/03/2026 on NASDAQ, with an aggregate market value of 123,837 and 213,273,469 shares outstanding. The 795 shares were acquired on 02/01/2026 via stock plan activity from the issuer.
Over the prior three months, Flammer has sold multiple blocks of INSM common stock, including 31,226 shares on 11/11/2025 for gross proceeds of 5,921,820 and 12,303 shares on 01/05/2026 for gross proceeds of 2,108,459.
Insmed insider Sara Bonstein has filed a Form 144 notice to sell 748 shares of common stock. The shares are to be sold through Merrill Lynch on the NASDAQ around 02/03/2026, with an aggregate market value of 116,938 based on the figure reported.
The 748 shares were acquired on 02/01/2026 through stock plan activity directly from the issuer. Over the prior three months, Bonstein reported additional sales of common stock, including 1,447 shares on 01/08/2026, 1,678 shares on 01/07/2026, and 1,517 shares on 01/06/2026, with gross proceeds of 252,023, 293,766, and 262,941, respectively.
Insmed (INSM) insider Martina Flammer has filed a Form 144 indicating an intention to sell 7,982 shares of the company’s common stock. The planned sale, through Merrill Lynch in Washington, D.C., has an aggregate market value of 1,233,964 and is listed for execution on 02/02/2026 on the NASDAQ.
The shares were acquired on 02/02/2026 via stock plan activity from the issuer. The notice also shows prior sales over the past three months, including 31,226 common shares sold on 11/11/2025 for gross proceeds of 5,921,820.
Insmed Inc. Chair and CEO William Lewis reported a series of option exercises and related stock sales on January 20, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. He exercised stock options to acquire 6,259 shares at an exercise price of $30.46 per share and 4,440 shares at $17.16 per share, both at a cost of $0 per derivative security.
On the same date, Lewis reported open-market sales of Insmed common stock in several tranches, including 1,006 shares at a weighted average price of $156.80, 1,243 shares at $158.37, 5,967 shares at $158.99, 2,229 shares at $159.85, and 254 shares at $160.70, with each weighted average representing sales within stated price ranges. Following these transactions, Lewis directly owned 306,891 shares of common stock and held options covering 75,109 and 53,280 shares in two grants. The filing also reports indirect ownership of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
BlackRock, Inc. has reported a significant ownership position in Insmed Inc. common stock. As of 12/31/2025, BlackRock beneficially owned 14,121,445 shares, representing 6.6% of the outstanding common stock. It held sole voting power over 13,203,800 shares and sole dispositive power over all 14,121,445 shares, with no shared voting or dispositive authority.
The shares are held across various BlackRock business units, and a range of underlying clients have rights to dividends and sale proceeds, but no single client has more than five percent of Insmed’s total outstanding common shares. BlackRock states that the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Insmed.
William Lewis filed a Rule 144 notice to sell 10,699 shares of common stock through Merrill Lynch on or about 01/20/2026, with the shares listed on NASDAQ. The filing shows these 10,699 shares were acquired from the issuer on 01/20/2026 via stock plan activity, with payment on the same date. The notice also lists the issuer’s common stock with 213,273,469 shares outstanding.
The document details prior sales by William Lewis over the past three months, including multiple common stock transactions between 12/04/2025 and 01/12/2026 with individual sale amounts ranging from 2,357 to 19,215 shares and corresponding gross proceeds disclosed for each trade.
Insmed Inc. (INSM) Chair and CEO William Lewis reported a series of option exercises and related stock sales on January 12, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. He exercised stock options for 6,259 shares of common stock at $30.46 per share and 4,440 shares at $17.16 per share, converting these into common shares.
On the same date he sold multiple blocks of Insmed common stock, including 3,974 shares at a weighted average price of $167.73 and 7,176 shares at $168.63, with additional smaller sales up to $174.86 per share. After these transactions, he directly owned 306,891 shares of common stock and indirectly held 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust. He also held 81,368 and 57,720 stock options remaining from the exercised grants.
Insmed Inc.'s Chief Medical Officer, Martina Flammer, reported a sale of company common stock. On January 9, 2026, she sold 1,887 shares of Insmed common stock at a price of $186.19 per share, as shown in Table I of the filing.
The filing states that this transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025. After this sale, Flammer beneficially owns 84,907 shares of Insmed common stock, held directly.
Insmed shareholder William Lewis has filed a notice of proposed stock sales under Rule 144. The filing covers the planned sale of 19,215 shares of Insmed common stock through Merrill Lynch on the NASDAQ around 01/12/2026, with an aggregate market value of 3,247,325. The company reports 213,273,469 shares of common stock outstanding. The shares to be sold were acquired through stock plan activity from the issuer on several dates in January 2026, including 10,699 shares on 01/12/2026. Over the prior three months, William Lewis sold additional Insmed common shares, including 10,699 shares on both 12/04/2025 and 12/18/2025, and smaller blocks in January 2026, with disclosed gross proceeds for each transaction.
Insmed Incorporated reported that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). The company will provide a live webcast of the presentation through the investor relations section of its website, allowing broader access for interested stakeholders. In connection with this conference appearance, Insmed issued a press release and prepared a slide presentation, which are included as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference for informational purposes but are not deemed filed under securities laws.